Table 2. Physical and laboratory data for first-onset lymphoma.
| PS (SE) | LDH (IU/L) (SE) |
sIL-2R (U/mL) (SE) |
β2M (mg/L) (SE) |
% Anti-HTLV-1 antibodypositive (n/N) | |
|---|---|---|---|---|---|
| Mature B-cell neoplasms | 0.8 (0.1) | 389 (76) | 2430 (639) | 3.3 (0.6) | 3.2 (2/61) |
| Diffuse large B-cell lymphoma | 1.0 (0.1) | 415 (77) | 1893 (340) | 2.7 (0.2) | 5.7 (2/35) |
| Follicular lymphoma | 0.6 (0.1) | 224 (27) | 4480 (2669) | 5.3 (2.6) | 0.0 (0/13) |
| Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue | 0.2 (0.2) | 193 (33) | 895 (394) | 1.8 (0.2) | 0.0 (0/5) |
| Burkitt lymphoma | 1.5 (1.5) | 2639 (2302) | 3724 (2873) | 4.4 (1.9) | 0.0 (0/2) |
| Mantle cell lymphoma | 0.0 (0.0) | 213 (50) | 3488 (2886) | 2.6 (1.2) | 0.0 (0/2) |
| Plasmacytoma | 0.5 (0.5) | 180 (1.0) | 334 (0) | 2.4 (0.0) | 0.0 (0/1) |
| Nodal marginal zone B-cell lymphoma | 0.0 (0.0) | 161 (0) | 175 (0) | 1.4 (0.0) | 0.0 (0/1) |
| B-cell lymphoma, unclassifiable | 1.3 (0.8) | 197 (30) | 1174 (992) | 2.4 (1.3) | 0.0 (0/2) |
| Mature T-cell and NK-cell neoplasms | 1.6 (0.3) | 982 (380) | 9243 (3881) | 8.4 (3.4) | 40.0 (6/15) |
| Adult T-cell leukemia/lymphoma | 1.6 (0.6) | 1418 (849) | 15082 (9350) | 13.3 (10.1) | 100.0 (6/6) |
| Peripheral T-cell lymphoma, not otherwise specified | 0.7 (0.2) | 1213 (636) | 4010 (1387) | 6.0 (2.0) | 0.0 (0/4) |
| Angioimmunoblastic T-cell lymphoma | 0.3 (0.3) | 325 (67) | 6533 (4187) | 9.5 (6.1) | 0.0 (0/3) |
| Anaplastic large cell lymphoma, ALK positive | 2.0 (2.0) | 202 (10) | 6257 (5371) | 2.4 (0.2) | 0.0 (0/2) |
| Composite B- and T-cell neoplasms | 3.0 (1.0) | 955 (479) | 6017 (3553) | 5.1 (0) | 0.0 (0/2) |
| Hodgkin lymphoma | 0.7 (0.2) | 179 (24) | 997 (596) | 2.6 (0.9) | 0.0 (0/4) |
| Total | 1.0 (0.1) | 486 (87) | 3607 (856) | 4.0 (0.7) | 9.7 (8/82) |
Eastern Cooperative Oncology Group Performance Status (PS), serum lactate dehydrogenase (LDH), soluble interleukin-2 receptor (sIL-2R), and β2-microglobulin (β2M) data are shown as the mean ± SE.
ALK, anaplastic lymphoma kinase; MALT, mucosa-associated lymphoid tissue; PS, Eastern Cooperative Oncology Group Performance Status; sIL-2R, soluble interleukin-2 receptor; β2M, β2-microglobulin; n.a., not assessed.